Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Human Papillomavirus | Research

Risk of cervical intraepithelial neoplasia grade 2 or worse in women aged ≥ 69 referred to colposcopy due to an HPV-positive screening test

Authors: Berit B. Booth, Mette Tranberg, Line W. Gustafson, Anne G. Christiansen, Helle Lapirtis, Lisa M. Krogh, Ina Marie D. Hjorth, Anne Hammer

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Cervical cancer incidence and mortality rates are high in older women in many developed countries, including Denmark. Therefore, Danish women aged 69 and older were invited for one additional human papilloma virus (HPV) based screening test in 2017. Here, we describe the clinical management and detection rate of cervical intraepithelial neoplasia grade 2 or worse (CIN2 +) in screen-positive women referred for colposcopy.

Methods

We conducted an observational study in public gynecology departments in Central Denmark Region, Denmark. Women were eligible for enrolment if they were aged 69 + in 2017, HPV positive on a screening test taken between April 20th, 2017, and December 31st, 2017, and had been referred for direct colposcopy. Data on participants’ characteristics, colposcopic findings, and histological outcomes were collected from medical records and the Danish Pathology Databank. We estimated the proportion of women with CIN2 + at the first colposcopy visit and at end of follow up including 95% confidence intervals (CIs).

Results

A total of 191 women were included with a median age of 74 years (IQR: 71—78). Most women (74.9%) did not have a fully visible transformation zone at colposcopy. At the first visit 170 women (89.0%) had a histological sample collected, 34 of whom (20.0%, 95% CI 14.3–26.8%) had CIN2 + diagnosed, 19 had CIN3 + , and two had cervical cancer). During follow-up additional CIN2 + were detected resulting in a total of 42 women (24.4%, 95% CI: 18.2–31.5%) being diagnosed with CIN2 + , 25 with CIN3 + , and three with cervical cancer. When restricting to women with paired histologic results (i.e., biopsies and a loop electrosurgical excision procedure (LEEP) specimen), we found that CIN2 + was missed in 17.9% (95% CI 8.9–30.4%) of biopsies compared to the LEEP.

Conclusion

Our findings suggest a potential risk of underdiagnosis in older postmenopausal women referred to colposcopy. Future studies should explore potential risk-markers for discrimination of women at increased risk of CIN2 + from those at low risk, as this would reduce risk of underdiagnosis and overtreatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hammer A, Kahlert J, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates in Denmark during 2002–2015: a registry-based cohort study. Acta Obstet Gynecol Scand. 2019;98(8):1063–9.CrossRefPubMed Hammer A, Kahlert J, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates in Denmark during 2002–2015: a registry-based cohort study. Acta Obstet Gynecol Scand. 2019;98(8):1063–9.CrossRefPubMed
2.
go back to reference Hammer A, Kahlert J, Rositch A, Pedersen L, Gravitt P, Blaakaer J, Soegaard M. The temporal and age-dependent patterns of hysterectomy-corrected cervical cancer incidence rates in Denmark: a population-based cohort study. Acta Obstet Gynecol Scand. 2017;96(2):150–7.CrossRefPubMed Hammer A, Kahlert J, Rositch A, Pedersen L, Gravitt P, Blaakaer J, Soegaard M. The temporal and age-dependent patterns of hysterectomy-corrected cervical cancer incidence rates in Denmark: a population-based cohort study. Acta Obstet Gynecol Scand. 2017;96(2):150–7.CrossRefPubMed
3.
go back to reference Hammer A, Soegaard V, Maimburg RD, Blaakaer J. Cervical cancer screening history prior to a diagnosis of cervical cancer in Danish women aged 60 years and older—A national cohort study. Cancer Medi. 2019;8(1):418–27.CrossRef Hammer A, Soegaard V, Maimburg RD, Blaakaer J. Cervical cancer screening history prior to a diagnosis of cervical cancer in Danish women aged 60 years and older—A national cohort study. Cancer Medi. 2019;8(1):418–27.CrossRef
4.
go back to reference Hammer A, Hee L, Blaakær J, Gravitt P. Temporal patterns of cervical cancer screening among Danish women 55 years and older diagnosed with cervical cancer. J Low Genit Tract Dis. 2018;22(1):1–7.CrossRefPubMed Hammer A, Hee L, Blaakær J, Gravitt P. Temporal patterns of cervical cancer screening among Danish women 55 years and older diagnosed with cervical cancer. J Low Genit Tract Dis. 2018;22(1):1–7.CrossRefPubMed
5.
go back to reference Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–101.CrossRefPubMed Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–101.CrossRefPubMed
6.
go back to reference Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32.CrossRefPubMed Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32.CrossRefPubMed
7.
go back to reference Castle PED, Stoler MHP, Wright TCP, Sharma AP, Wright TLMD, Behrens CMMD. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880–90.CrossRefPubMed Castle PED, Stoler MHP, Wright TCP, Sharma AP, Wright TLMD, Behrens CMMD. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880–90.CrossRefPubMed
8.
go back to reference Gustafson LW, Hammer A, Bennetsen MH, Kristensen CB, Majeed H, Petersen LK, et al. Cervical intraepithelial neoplasia in women with transformation zone type 3: cervical biopsy versus large loop excision. BJOG: an international journal of obstetrics and gynaecology. 2022;129(13):2132–40. Gustafson LW, Hammer A, Bennetsen MH, Kristensen CB, Majeed H, Petersen LK, et al. Cervical intraepithelial neoplasia in women with transformation zone type 3: cervical biopsy versus large loop excision. BJOG: an international journal of obstetrics and gynaecology. 2022;129(13):2132–40.
9.
go back to reference Gustafson LW, Petersen LK, Bor P, Andersen B, Hammer A. Cervical cancer prevention among older women - challenges in screening, diagnostic workup, and treatment. Acta Obstet Gynecol Scand. 2021;100(8):1364–8.CrossRefPubMed Gustafson LW, Petersen LK, Bor P, Andersen B, Hammer A. Cervical cancer prevention among older women - challenges in screening, diagnostic workup, and treatment. Acta Obstet Gynecol Scand. 2021;100(8):1364–8.CrossRefPubMed
10.
go back to reference Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki A-B, Nayar R, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102–31.CrossRefPubMedPubMedCentral Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki A-B, Nayar R, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102–31.CrossRefPubMedPubMedCentral
11.
go back to reference Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004;191(2):430–4.CrossRefPubMed Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004;191(2):430–4.CrossRefPubMed
15.
go back to reference Danish Government DR, Danish Municipalities. Action plan for cancer plan IV (2017–2020). 2017. Danish Government DR, Danish Municipalities. Action plan for cancer plan IV (2017–2020). 2017.
16.
go back to reference DKLS. Resultater fra Engangstilbuddet: Livmoderhalskræftscreening blandt danske kvinder født før 1948 1. delrapport. 2019. DKLS. Resultater fra Engangstilbuddet: Livmoderhalskræftscreening blandt danske kvinder født før 1948 1. delrapport. 2019.
17.
go back to reference St-Martin G, Viborg PH, Andersen ABT, Andersen B, Christensen J, Ejersbo D, Heje HN, Jochumsen KM, Johansen T, Larsen LG, et al. Histological outcomes in HPV-screened elderly women in Denmark. PLoS One. 2021;16(2):e0246902–e0246902.CrossRefPubMedPubMedCentral St-Martin G, Viborg PH, Andersen ABT, Andersen B, Christensen J, Ejersbo D, Heje HN, Jochumsen KM, Johansen T, Larsen LG, et al. Histological outcomes in HPV-screened elderly women in Denmark. PLoS One. 2021;16(2):e0246902–e0246902.CrossRefPubMedPubMedCentral
19.
go back to reference Quaas J, Reich O, Küppers V. Explanation and use of the Rio 2011 colposcopy nomenclature of the IFCPC (International Federation for Cervical Pathology and Colposcopy): comments on the general colposcopic assessment of the uterine cervix: adequate/inadequate; squamocolumnar junction; transformation zone. Geburtshilfe und Fraunenheilkunde. 2014;74(12):1090–2. https://doi.org/10.1055/s-0034-1383216. Quaas J, Reich O, Küppers V. Explanation and use of the Rio 2011 colposcopy nomenclature of the IFCPC (International Federation for Cervical Pathology and Colposcopy): comments on the general colposcopic assessment of the uterine cervix: adequate/inadequate; squamocolumnar junction; transformation zone. Geburtshilfe und Fraunenheilkunde. 2014;74(12):1090–2. https://​doi.​org/​10.​1055/​s-0034-1383216.
20.
go back to reference Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–6.CrossRefPubMedPubMedCentral Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–6.CrossRefPubMedPubMedCentral
21.
22.
go back to reference Richart RM. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1967;10(4):748–84.CrossRef Richart RM. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1967;10(4):748–84.CrossRef
23.
go back to reference Hammer A, Rositch A, Qeadan F, Gravitt PE, Blaakaer J. Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis. Int J Cancer. 2016;138(12):2795–803.CrossRefPubMed Hammer A, Rositch A, Qeadan F, Gravitt PE, Blaakaer J. Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis. Int J Cancer. 2016;138(12):2795–803.CrossRefPubMed
24.
go back to reference Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208–103208.CrossRefPubMedPubMedCentral Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208–103208.CrossRefPubMedPubMedCentral
25.
go back to reference Sahlgren H, Elfström KM, Lamin H, Carlsten-Thor A, Eklund C, Dillner J, Elfgren K. Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. Am J Obstet Gynecol. 2020;222(3):253.e251-253.e258.CrossRef Sahlgren H, Elfström KM, Lamin H, Carlsten-Thor A, Eklund C, Dillner J, Elfgren K. Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. Am J Obstet Gynecol. 2020;222(3):253.e251-253.e258.CrossRef
26.
go back to reference Bergengren L, Karlsson MG, Helenius G. Prevalence of HPV and pathological changes among women 70 years of age, 10 years after exclusion from the Swedish cervical cancer screening program. Cancer Causes Control. 2020;31(4):377–81.CrossRefPubMed Bergengren L, Karlsson MG, Helenius G. Prevalence of HPV and pathological changes among women 70 years of age, 10 years after exclusion from the Swedish cervical cancer screening program. Cancer Causes Control. 2020;31(4):377–81.CrossRefPubMed
27.
go back to reference Cheung LC, Egemen D, Chen X, Katki HA, Demarco M, Wiser AL, Perkins RB, Guido RS, Wentzensen N, Schiffman M. 2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation. J Low Genit Tract Dis. 2020;24(2):90–101.CrossRefPubMedPubMedCentral Cheung LC, Egemen D, Chen X, Katki HA, Demarco M, Wiser AL, Perkins RB, Guido RS, Wentzensen N, Schiffman M. 2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation. J Low Genit Tract Dis. 2020;24(2):90–101.CrossRefPubMedPubMedCentral
28.
go back to reference Bergengren L, Lillsunde-Larsson G, Helenius G, Karlsson MG. HPV-based screening for cervical cancer among women 55–59 years of age. PLoS One. 2019;14(6):e0217108–e0217108.CrossRefPubMedPubMedCentral Bergengren L, Lillsunde-Larsson G, Helenius G, Karlsson MG. HPV-based screening for cervical cancer among women 55–59 years of age. PLoS One. 2019;14(6):e0217108–e0217108.CrossRefPubMedPubMedCentral
29.
go back to reference O’Connor M, Gallagher P, Waller J, Martin CM, O’Leary JJ, Sharp L. Adverse psychological outcomes following colposcopy and related procedures: a systematic review. BJOG. 2016;123(1):24–38.CrossRefPubMed O’Connor M, Gallagher P, Waller J, Martin CM, O’Leary JJ, Sharp L. Adverse psychological outcomes following colposcopy and related procedures: a systematic review. BJOG. 2016;123(1):24–38.CrossRefPubMed
30.
go back to reference Forss A, Tishelman C, Widmark C, Sachs L. Women’s experiences of cervical cellular changes: an unintentional transition from health to liminality? Sociol Health Illn. 2004;26(3):306–25.CrossRefPubMed Forss A, Tishelman C, Widmark C, Sachs L. Women’s experiences of cervical cellular changes: an unintentional transition from health to liminality? Sociol Health Illn. 2004;26(3):306–25.CrossRefPubMed
31.
go back to reference Swancutt DR, Greenfield SM, Luesley DM, Wilson S. Women’s experience of colposcopy: a qualitative investigation. BMC Womens Health. 2011;11(1):11–11.CrossRefPubMedPubMedCentral Swancutt DR, Greenfield SM, Luesley DM, Wilson S. Women’s experience of colposcopy: a qualitative investigation. BMC Womens Health. 2011;11(1):11–11.CrossRefPubMedPubMedCentral
32.
go back to reference Hellsten C, Sjostrom K, Lindqvist PG. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG. 2008;115(2):212–8.CrossRefPubMed Hellsten C, Sjostrom K, Lindqvist PG. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG. 2008;115(2):212–8.CrossRefPubMed
33.
go back to reference Gustafson LW, Larsen MB, Hammer A, Petersen LK, Andersen B, Bor P. Levels of anxiety in women aged ≥45 years undergoing diagnostic large loop excision of the transformation zone: a longitudinal study. BJOG. 2023;130(2):192–200.CrossRefPubMed Gustafson LW, Larsen MB, Hammer A, Petersen LK, Andersen B, Bor P. Levels of anxiety in women aged ≥45 years undergoing diagnostic large loop excision of the transformation zone: a longitudinal study. BJOG. 2023;130(2):192–200.CrossRefPubMed
34.
go back to reference Kirkegaard P, Gustafson LW, Petersen LK, Andersen B. ‘I want the whole package’. Elderly patients’ preferences for follow-up after abnormal cervical test results: a qualitative study. Patient Prefer Adherence. 2020;14:1185–93.CrossRefPubMedPubMedCentral Kirkegaard P, Gustafson LW, Petersen LK, Andersen B. ‘I want the whole package’. Elderly patients’ preferences for follow-up after abnormal cervical test results: a qualitative study. Patient Prefer Adherence. 2020;14:1185–93.CrossRefPubMedPubMedCentral
35.
go back to reference Gravitt PE, Landy R, Schiffman M. How confident can we be in the current guidelines for exiting cervical screening? Prev Med. 2018;114:188–92.CrossRefPubMed Gravitt PE, Landy R, Schiffman M. How confident can we be in the current guidelines for exiting cervical screening? Prev Med. 2018;114:188–92.CrossRefPubMed
36.
go back to reference Gyllensten U, Gustavsson I, Lindell M, Wilander E. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012;125(2):343–5.CrossRefPubMed Gyllensten U, Gustavsson I, Lindell M, Wilander E. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012;125(2):343–5.CrossRefPubMed
37.
go back to reference Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011;6(9):1083–98.CrossRefPubMed Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011;6(9):1083–98.CrossRefPubMed
38.
go back to reference Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W, Wentzensen N. Five-year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women. JAMA Oncol. 2018;5(2):181–6.CrossRefPubMedCentral Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W, Wentzensen N. Five-year risk of cervical precancer following p16/Ki-67 dual-stain triage of HPV-positive women. JAMA Oncol. 2018;5(2):181–6.CrossRefPubMedCentral
39.
go back to reference Gustafson LW, Tranberg M, Christensen PN, Brøndum R, Wentzensen N, Clarke MA, et al. Clinical utility of p16/Ki67 dual stain cytology for detection of cervical intraepithelial neoplasia grade two or worse in women with a transformation zone type 3: a cross sectional study. BJOG. 2023;130(2):202–9. Gustafson LW, Tranberg M, Christensen PN, Brøndum R, Wentzensen N, Clarke MA, et al. Clinical utility of p16/Ki67 dual stain cytology for detection of cervical intraepithelial neoplasia grade two or worse in women with a transformation zone type 3: a cross sectional study. BJOG. 2023;130(2):202–9.
40.
go back to reference Andersen B, Christensen BS, Christensen J, Ejersbo D, Heje HN, Jochumsen KM, Johansen T, Larsen LG, Lynge E, Serizawa R, et al. HPV-prevalence in elderly women in Denmark. Gynecol Oncol. 2019;154(1):118–23.CrossRefPubMed Andersen B, Christensen BS, Christensen J, Ejersbo D, Heje HN, Jochumsen KM, Johansen T, Larsen LG, Lynge E, Serizawa R, et al. HPV-prevalence in elderly women in Denmark. Gynecol Oncol. 2019;154(1):118–23.CrossRefPubMed
Metadata
Title
Risk of cervical intraepithelial neoplasia grade 2 or worse in women aged ≥ 69 referred to colposcopy due to an HPV-positive screening test
Authors
Berit B. Booth
Mette Tranberg
Line W. Gustafson
Anne G. Christiansen
Helle Lapirtis
Lisa M. Krogh
Ina Marie D. Hjorth
Anne Hammer
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10888-1

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine